Hospira Infusion Systems
Division of ICU Medical Inc.
Latest From Hospira Infusion Systems
In Medtech Insight's latest rankings of top 100 revenue-earners in the medical device and diagnostics sector, it was steady as she goes for most of the multinational medtechs, with some major exceptions. But there will be more M&A reflected in next year's ranking based on 2018 revenues. Also, medtech groups leading the global market tightened their grip further in 2017, as providers chose to partner more and more with fewer suppliers who can offer a wider provision of services.
A newly unsealed whistleblower suit filed in Illinois federal court in 2016 alleges the company failed to alert US FDA or customers to software and power cable issues that could have harmed patients and users. Pfizer, which purchased Hospira in 2015 and sold the infusion pump unit in 2017, says the case has no merit, and the government has declined to intervene.
Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.
While infusion pumps are vital to patient care and used in abundance in hospitals, they are also associated with numerous errors. One of the keys to addressing this problem lies in improving the devices’ interoperability with hospital IT systems, and as those changes are starting to materialize, so are opportunities for new players in this space.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.